Lupin gains on launching generic Tobramycin Inhalation Solution USP in US

14 Jun 2018 Evaluate

Lupin is currently trading at Rs. 878.55, up by 8.95 points or 1.03% from its previous closing of Rs. 869.60 on the BSE.

The scrip opened at Rs. 876.25 and has touched a high and low of Rs. 885.05 and Rs. 863.50 respectively. So far 160394 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1194.00 on 15-Jun-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 885.05 and Rs. 764.00 respectively. The current market cap of the company is Rs. 39741.61 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.

Pharmaceuticals Corporation’s Tobi 300 mg/5 ml

Lupin has launched its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of around $99 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×